Supposedly the design of the trial was done very well. While we often hear stats from the drug companies stating "reduction in risk", the bottom line in this trial was to compare disease progression level between those who used interferon beta and those who used nothing. And it was here they found no difference!!

But if you read the literature of the companies who produce this drug, you would get a totally different outlook. Ah the importance of marketing and how it can influence people to use something even though it may not give you what was inferred. The CRAB drug producers have been doing this for years and making a ton of money along the way. Too bad most MS patients haven't benefited much if at all.